A societal perspective is common according to the health economic guidelines. Currently there is interest to even include broader effects (i.e. exceeding the patient and exceeding health care) . This is especially relevant to illness in children and disorders, which have a high impact on third parties (such as ADHD). iMTA develops models that adds to the current movement towards broader considerations in cost-effectiveness analyses.
In our recent study into ADHD among adolescents it was shown that key cost-drivers for ADHD are health care consumption (i.e. psychological treatment). Interestingly, costs of this disease were also caused by parents, who suffer loss of productivity as they face absence from work and lower productivity at work. For the mother of the child, lower levels of quality of life are reported.